Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Benzinga

19 Aug 2021

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.
Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.
The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).
Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).
Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).
There were no safety issues or venous ulcer recurrences.
The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.
Related: FDA Breakthrough Designation For Its Venous Insufficiency Device.
Price Action: HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.

See more from Benzinga

Click here for options trades from Benzinga
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
NLS Pharma Stock Gains After Issuance Of Mazindol Patent

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2160250793"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2160250793\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2160250793?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/W1VU5NXoeOklS4J17UGuUA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Bih0obOqAiTJL3YNmgwYhg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d","is_english":true,"pubTime":"2021-08-19 23:49","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2160250793","market":"us","top_or_hot":-1,"title":"Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/VRSnnXWuZ5LiJ.XdtF0LPA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Hancock Jaffe Laboratories Inc</strong> (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.</li>\n<li>Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.</li>\n<li>The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).</li>\n<li>Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).</li>\n<li>Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).</li>\n<li>There were no safety issues or venous ulcer recurrences.</li>\n<li>The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.</li>\n<li><em>Related: </em><em>FDA Breakthrough Designation For Its Venous Insufficiency Device</em><em>.</em></li>\n<li><strong>Price Action:</strong> HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action</li>\n<li>NLS Pharma Stock Gains After Issuance Of Mazindol Patent</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.\nData will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HBHC","symbol_name":"汉考克控股银行","start_time":0,"source_url":"https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html","article_id":"2160250793","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/W1VU5NXoeOklS4J17UGuUA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Bih0obOqAiTJL3YNmgwYhg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2160250793","pubTimestamp":1629388195,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HBHC":"汉考克控股银行"},"translate_title":"汉考克·贾菲强调静脉功能不全瓣膜的两年数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HBHC":1,"HJLI":0.9},"content_text":"Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.\nData will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.\nThe results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).\nDisease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).\nPain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).\nThere were no safety issues or venous ulcer recurrences.\nThe VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.\nRelated: FDA Breakthrough Designation For Its Venous Insufficiency Device.\nPrice Action: HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nGalmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action\nNLS Pharma Stock Gains After Issuance Of Mazindol Patent\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}